Elamipretide

Elamipretide

Clinical data
Other names	H-D-Arg-Tyr(2,6-diMe)-Lys-Phe-NH2; D-Arginyl-2,6-dimethyl-L-tyrosyl-L-lysyl-L-phenylalaninamide
Identifiers
IUPAC name (2S)-6-Amino-2-[[(2S)-2-[[(2R)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]amino]-N-[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]hexanamide
CAS Number	736992-21-5
PubChem CID	11764719
UNII	87GWG91S09
KEGG	D10925
CompTox Dashboard (EPA)	DTXSID50471988
Chemical and physical data
Formula	C32H49N9O5
Molar mass	639.802 g·mol−1
InChI InChI=1S/C32H49N9O5/c1-19-15-22(42)16-20(2)23(19)18-27(41-29(44)24(34)11-8-14-38-32(36)37)31(46)39-25(12-6-7-13-33)30(45)40-26(28(35)43)17-21-9-4-3-5-10-21/h3-5,9-10,15-16,24-27,42H,6-8,11-14,17-18,33-34H2,1-2H3,(H2,35,43)(H,39,46)(H,40,45)(H,41,44)(H4,36,37,38)/t24-,25+,26+,27+/m1/s1 Key:SFVLTCAESLKEHH-WKAQUBQDSA-N

Elamipretide (also known as SS-31, , MTP-131 and Bendavia) is a small mitochondrially-targeted tetrapeptide (D-Arg-dimethylTyr-Lys-Phe-NH₂) that appears to reduce the production of toxic reactive oxygen species and stabilize cardiolipin.

Stealth Peptides, a privately held company, was founded in 2006 to develop intellectual property licensed from several universities including elamipretide; it subsequently changed its name to Stealth BioTherapeutics.

As of November 2017 Stealth had obtained an orphan designation in the US for use in mitochondrial myopathy and had started a Phase III trial in that indication. As of January 2020, trial expectations were not met.